C. Namour

Definitions, outcomes, and management of hyperprogression in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors.

A. Cazes, G. Zalcman, B. Besse, 2020, Lung cancer.

Efficacy of SARS-CoV-2 vaccine in thoracic cancer patients: a prospective study supporting a third dose in patients with minimal serologic response after two vaccine doses

E. Vicaut, C. Charpentier, G. Zalcman, 2021, medRxiv.

Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.

A. Cazes, G. Zalcman, C. Danel, 2019, Lung cancer.

Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)

N. Magné, B. Chauffert, F. Ducray, 2020, European Journal of Cancer.

Patients avec cancers thoraciques et COVID-19 : au cœur de la tempête

V. Gounant, S. Brosseau, C. Namour, 2021, Revue des Maladies Respiratoires Actualités.